Abivax SA (ABVX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.157x

Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.157x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-71.28 Million ≈ $-83.34 Million USD) by net assets (€455.20 Million ≈ $532.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abivax SA net asset quality index to measure how much of total assets are equity-financed.

Abivax SA - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Abivax SA (ABVX) long-term investment share to see how much of total assets are deployed in long-term investments.

Abivax SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Quinenco SN:QUINENCO	0.092x
Vibra Energia S.A. SA:VBBR3	0.136x
GETLINK ADR EO-40 F:TNU	N/A
Nippon Life India Asset Management Limited NSE:NAM-INDIA	0.125x
Valmont Industries Inc NYSE:VMI	0.068x
Canadian Utilities Limited TO:CU	0.069x
Redeia Corporacion S.A. MC:RED	0.027x
NTPC Green Energy Limited NSE:NTPCGREEN	0.059x

Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ABVX market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€455.20 Million ≈ $532.18 Million	€-162.09 Million ≈ $-189.50 Million	-0.356x	+90.62%
2024-12-31	€40.58 Million ≈ $47.45 Million	€-154.07 Million ≈ $-180.13 Million	-3.796x	-666.11%
2023-12-31	€196.01 Million ≈ $229.16 Million	€-97.13 Million ≈ $-113.56 Million	-0.496x	+98.58%
2022-12-31	€1.88 Million ≈ $2.20 Million	€-65.58 Million ≈ $-76.67 Million	-34.845x	-2096.03%
2021-12-31	€28.77 Million ≈ $33.64 Million	€-45.66 Million ≈ $-53.38 Million	-1.587x	+75.14%
2020-12-31	€4.67 Million ≈ $5.46 Million	€-29.82 Million ≈ $-34.87 Million	-6.382x	-173.67%
2019-12-31	€11.78 Million ≈ $13.77 Million	€-27.47 Million ≈ $-32.12 Million	-2.332x	-453.39%
2018-12-31	€34.65 Million ≈ $40.51 Million	€-14.60 Million ≈ $-17.07 Million	-0.421x	-140.30%
2017-12-31	€48.18 Million ≈ $56.33 Million	€-8.45 Million ≈ $-9.88 Million	-0.175x	+36.28%
2016-12-31	€56.72 Million ≈ $66.31 Million	€-15.61 Million ≈ $-18.25 Million	-0.275x	-32.46%
2015-12-31	€71.74 Million ≈ $83.87 Million	€-14.90 Million ≈ $-17.42 Million	-0.208x	-113.32%
2014-12-31	€33.94 Million ≈ $39.67 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	-0.25%
2013-12-31	€34.02 Million ≈ $39.77 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$10.08 Billion

€8.62 Billion EUR

Market Cap Rank

#2552 Global

#53 in France

Share Price

€108.70

Change (1 day)

+1.30%

52-Week Range

€58.80 - €135.00

All Time High

€135.00